Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEMCAR19: Allogeneic CD19-CAR Memory T Cells for Relapsed/Refractory CD19+ Leukemia
NCT04881240Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Feb 2024
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD19-CAR.CD45RA-negative T-cells in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose-Limiting Toxicities at 4 weeks. Started Feb 2024; status: recruiting.
02
Drugs
CD19-CAR.CD45RA-negative T-cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04881240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04881240.